Tag

Intranasal

All articles tagged with #intranasal

Promising Results for Intranasal COVID Vaccine in Early Trials
health2 years ago

Promising Results for Intranasal COVID Vaccine in Early Trials

Codagenix has announced promising findings for its live-attenuated intranasal COVID vaccine candidate, CoviLiv, which prompted robust humoral and cellular immunity in adults during a phase 1 clinical trial. The vaccine, developed in collaboration with the Serum Institute of India, is currently undergoing a phase 3 efficacy trial as part of the WHO Solidarity vaccine trials. Intranasal vaccines are attractive for their needle-free formulation and potential to stimulate mucosal immunity. Codagenix's vaccine, which is easy to administer and doesn't require refrigeration, may be more appealing for use in low-resource settings. The vaccine mimics natural infection and induces a specific type of local immune response, potentially contributing to hybrid immunity.

Nasal COVID vaccine shows promise.
health2 years ago

Nasal COVID vaccine shows promise.

Clinical trials are underway for an intranasal COVID-19 vaccine that is administered by spraying into the nose, not injecting into the arm. The hope is that a nasal vaccine would be even better at preventing mild illness by inducing immunity in the mucosa of the nasal pharynx, the site of initial viral replication, and may prevent infection and reduce transmission. Nasal vaccines work to immediately strengthen antibodies in the mucus and nose, preventing infection before the virus is able to spread throughout the body. While nasal vaccine doses have already been approved for use in some other parts of the world, they are still in the early stages of human trials in the U.S.

Nasal COVID vaccine shows promise.
health2 years ago

Nasal COVID vaccine shows promise.

Clinical trials are underway for a new type of intranasal COVID-19 vaccine that is administered by spraying into the nose, not injecting into the arm. The hope is that a nasal vaccine would be even better at preventing mild illness by inducing immunity in the mucosa of the nasal pharynx, the site of initial viral replication, and may prevent infection and reduce transmission. While nasal vaccine doses have already been approved for use in some other parts of the world, they are likely still a ways off for the United States.